Objective: The aim of the present study was to evaluate the impact of metabolic syndrome (MetS) on benign prostatic hyperplasia (BPH) in elderly Chinese men. Methods: A total of 401 elderly BPH patients were divided into the without or with MetS group to assess the associations of MetS and components of MetS with BPH. Urologic evaluation included prostate volume, International Prostate Symptom Score, serum prostate-specific antigen, duration of concomitant lower urinary tract symptoms (LUTS) and maximum flow rate. Results: Body mass index (BMI), waist circumference, fasting glucose, glycosylated hemoglobin, triglyceride, fasting insulin (FINS), insulin resistance assessed by homeostasis model assessment (HOMA-IR) were greater and high-density lipoprotein cholesterol (HDL-C) was lower in BPH patients with MetS than in those without MetS. The patients with MetS showed a significantly larger prostate volume (p = 0.000) and longer duration of LUTS (p = 0.006) than those without MetS. Prostate volume was positively correlated with BMI (p = 0.000), FINS (p = 0.001), HOMA-IR (p = 0.003) and inversely correlated with HDL-C (p = 0.000). Multiple linear regression analysis showed that prostate volume was significantly correlated with HOMA-IR (p = 0.015). Conclusions: Our results suggest that MetS, BMI, low HDL-C level, increased serum insulin and especially insulin resistance are considered risk factors for prostate enlargement in elderly Chinese men.

Keywords:
Benign prostatic hyperplasia, Metabolic syndrome, Lower urinary tract symptoms, Prostate volume, Insulin resistance
1.
Wei JT, Calhoun E, Jacobsen SJ: Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2008;179(5 suppl):S75-S80.
2.
Isaacs JT, Coffey DS: Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
3.
Nandeesha H, Koner BC, Dorairajan LN, Sen SK: Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006;370:89-93.
4.
Hammarsten J, Högstedt B: Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-158.
5.
Lee S, Min HG, Choi SH, Kim YJ, Oh SW, Kim YJ, Park Y, Kim SS: Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 2006;14:172-179.
6.
Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A: Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008;179:1891-1895.
7.
Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA: Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 2012;110:540-545.
8.
Churilla JR, Fitzhugh EC, Thompson DL: The metabolic syndrome: how definition impacts the prevalence and risk in U.S. adults: 1999-2004 NHANES. Metab Syndr Relat Disord 2007;5:331-342.
9.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
10.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
11.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A: The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-203; discussion 204-206.
12.
Hammarsten J, Högstedt B, Holthuis N, Mellström D: Components of the metabolic syndrome - risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-162.
13.
Jeong JH, Kim EK, Kim DK: Association of metabolic syndrome and benign prostate enlargement in young Korean males. Korean J Urol 2011;52:757-762.
14.
Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA: Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-2568.
15.
Vikram A, Jena G, Ramarao P: Insulin-resistance reduces botulinum neurotoxin-type A induced prostatic atrophy and apoptosis in rats. Eur J Pharmacol 2011;650:356-363.
16.
Gupta A, Gupta V: Metabolic syndrome: what are the risks for humans? Biosci Trends 2010;4:204-212.
17.
Landsberg L: Diet, obesity and hypertension: a hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-1090.
18.
Hautanen A: Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 2000;24(S2):S64-S70.
19.
Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, Cruz F: Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur Urol 2009;56:134-140.
20.
Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA, Demayo F, Greenberg NM: Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene 2008;27:2868-2876.
21.
Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, Paikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C, Marberger M: Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003;83:1131-1146.
22.
Song L, Zhu Y, Han P, Chen N, Lin D, Lai J, Wei Q: A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen. Urology 2011;77:688-692.
23.
Vignozzi L, Gacci M, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastanelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M: Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013;73:789-800.
24.
Gacci M, Vignozzi L, Sebastanelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M: Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101-106.
25.
Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405-409.
26.
Suzuki K, Ito K, Ichinose Y, Kurokawa K, Suzuki T, Imai K, Yamanaka H, Honma S: Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995;29:65-68.
27.
Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M: Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011;25:337-353.
28.
Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M: Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012;21:71-84.
29.
Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C, Peeker R, Smith U, Mellström D: Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2009;12:160-165.
30.
Rohrmann S, Smit E, Giovannucci E, Platz EA: Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005;29:310-316.
31.
Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, Mollon P, Tamimi N, Rosen RC, McKinlay JB: Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009;182:616-624; discussion 624-625.
32.
Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, Hu Y, Zhang Y, Liao M, Mo Z: Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology 2012;79:194-201.
33.
Yeh HC, Liu CC, Lee YC, Wu WJ, Li WM, Li CC, Hour TC, Huang CN, Chang CF, Huang SP: Associations of the lower urinary tract symptoms with the lifestyle, prostate volume, and metabolic syndrome in the elderly males. Aging Male 2012;15:166-172.
34.
McVary KT, Rademaker A, Lloyd GL, Gann P: Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005;174:1327-1333.
35.
Erickson BA, Vaughan-Sarrazin M, Liu X, Breyer BN, Kreder KJ, Cram P: Lower urinary tract symptoms and diet quality: findings from the 2000-2001 National Health and Nutrition Examination Survey. Urology 2012;79:1262-1267.
36.
Parsons JK: Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010;5:212-218.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.